NOTE: Latest Info and Disclaimer (supersedes any previous one for HQNTE).
FOR SHAREHOLDER PACKET:
Email: igi@wans.net
Phone: 1-703-821-3434
ADDITIONAL INFORMATION AND COMPENSATION DISCLOSURE -- Please Read Completely Before Considering An Investment
COMPANY BACKGROUND
H-QUOTIENT, INC. is a publicly traded company that creates and produces state-of-the art computer software systems that collect and act upon real-time information critical to improving the delivery of healthcare. They have also recently announced the acquisition of a healthcare distribution business expected to immediately accretive to earnings (see PR lin below) Company Website: hquotient.com
Their Products
hquotient.com
Significant New Management
** Larry Burden, a former Senior V.P. and CIO of Freddie Mac, has been appointed as VP of Operations to market their medical products, including LabQuotient, which they announced publicly should add $5M Net to their bottom line. (PR link below)
** Dr. Laipply, Nichols Institute at Qeust Diagnostics, has also joined H-Quotient as Chairman of the H-Quotient, Inc., Scientific Advisory Board. (PR link below)
STARTER D.D. -- please conduct your own Due Diligence
** Two year high/low: $7.00+ to .16
** Shares O/S = 25M (12M float) – approx.
RECENT CHART
bigcharts.marketwatch.com.
RECENT DEVELOPMENTS
** Announced unaudited net earnings from operations in excess of $1M; (See PR link and more info below). Also mentioned the "e" for the late filing and discussed its removal. Current symbol: HQNTE.
** Announced $5M Projected "Net" for LabQuotient (see PR below)
** Announced recent acquisition of a healthcare distribution business that the company expects to have an immediate accretive impact on earnings. (see PR link below)
** Added two high quality team members recently (who presumably did their own DD on the company)
(1) Dr. Thomas Laipply, Dir. of Molecular Tissue Pathology, Nichols Institute at Quest Diagnostics (see recent PR's below) and his share purchases in the open market.
(2) Laurence Burden, V.P. of Operations, to help market HQNT’s medical software products. Look at his resume (from recent PR below)
- "As corporate VP and Chief Information Officer (CIO) and member of the turnaround team, he helped make possible the $2.3 billion sale of Firestone to Bridgestone" Also, "As Senior VP and CIO of Freddie Mac, he redesigned its computer systems and financial engineering systems, providing the basis for hundreds of millions in revenues and savings."
FILING INFO AND RECENT NEWS
Please verify yourself these and other figures below by viewing all the current filings at: siliconinvestor.com and especially the new filing when it comes out.
****
H-Quotient, Inc., Announces Record Annual Earnings (and the "e")
VIENNA, Va., Apr 19, 2002 /PRNewswire-FirstCall via COMTEX/ -- H-Quotient, Inc., (OTC Bulletin Board: HQNT chart, msgs) announced earnings from operations in excess of 1,000,000 for the year ending December 31, 2001, compared with losses in every prior year. Additional earnings were recorded from investments through our subsidiary Quotient Capital Corporation.
siliconinvestor.com
****
H-Quotient, Inc., Announces LabQuotient; $5 Million Net Projected
VIENNA, Va., Mar 25, 2002 /PRNewswire-FirstCall via COMTEX/ -- H-Quotient, Inc., (OTC Bulletin Board: HQNT chart, msgs) and Dr. Thomas C. Laipply, MD, FCAP, FIAP, Director of Molecular Tissue Pathology, Nichols Institute at Quest Diagnostics announced LabQuotient, a relational database for improving and monitoring medical test ordering. The product is expected to be ready for market this summer. Pre-production orders have been received. Further details will be announced in a subsequent release.
****
H-Quotient, Inc., is projected to earn net income of $5 million in the product's first year. All income will be recurring and is expected to grow substantially because the universe for this revolutionary product includes clinical doctors, dentists, veterinarians, emergency rooms, urgent care centers, insurance companies, HMOs, hospital quality assurance personnel, commercial laboratories, and pharmaceutical-drug companies.
****
H-Quotient, Inc., Announces Appointment of Laurence T. Burden As V.P. of Operations ---- Check his resume:
siliconinvestor.com
****
H-Quotient, Inc., Announces Scientific Advisory Board Chairman
siliconinvestor.com
****
H-Quotient, Inc., Announces More Than 1 Million Shares Purchased by Dr. Laipply
siliconinvestor.com
****
H-Quotient, Inc. Announces LabQuotient Prototype; Full-Scale Sales Effort to Commence
siliconinvestor.com
****
H-Quotient, Inc., Announces Development of Blood Utilization Software
siliconinvestor.com
****
OTHER NEWS: Recent Acquisition
siliconinvestor.com
Do your own DD. E-Mail: Investor Relations at:igi@wans.net
for a shareholder packet.
DISCLAIMER: PLEASE READ BEFORE CONSIDERING AN INVESTMENT IN H-QUOTIENT: As always, do your own Due Diligence. The information posted by me is believed to be accurate, but cannot be guaranteed. Some forward-looking statements or opinions expressed by myself or others on this thread or others may not prove to be true. I was retained by the on April 9th, 2002, and am being compensated with 15K shares of restriced stock for providing honest information that hopefully will encourage individuals to do their own Due Diligence and become long term shareholders. Because of the "restricted" status, I cannot sell any of the shares until at least April of 2003. I will be only be supplying information that is already in the public domain; in other words previously disclosed information by the Company, as per Reg FD. It is up to each individual to do their own DD. I also currently hold 6,500 shares of stock that I purchased on the open market from 57 to 74 cents recently. Please visit the SEC'S website at sec.gov or the company's website at hquotient.com if interested. |
